A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study is a multi center, open-label, dose escalation, Phase I/IIa study of EF-009 in up
to 30 patients with borderline resectable and unresectable pancreatic cancer.